MedTrace Logo

Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients

NCT02099838 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2014-06-25

Study results available
· View outcomes & findings →

Summary

Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients. This study was designed to evaluate the effectiveness and safety of adding compound preparation of pioglitazone and metformin for type 2 diabetic patients who have bad glycemic control with the initial treatment of SUs.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Pioglitazone and Metformin

taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks

DRUG

Placebo

taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks

Sponsors & Collaborators

  • Wuhan Iron and Steel Workers' Hospital

    collaborator OTHER

  • Wuhan Pu-Ai Hospital

    collaborator OTHER

  • Hubei Xinhua Hospital

    collaborator OTHER

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xuefeng Yu, MD, PhD · Division of Endocrinology, Tongji Hospital, Huazhong University of Science & Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099838 on ClinicalTrials.gov